The University of Chicago Header Logo

Connection

Thomas Gajewski to Antigens, CD

This is a "connection" page, showing publications Thomas Gajewski has written about Antigens, CD.
Connection Strength

1.422
  1. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400.
    View in: PubMed
    Score: 0.449
  2. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
    View in: PubMed
    Score: 0.114
  3. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15; 156(8):2909-17.
    View in: PubMed
    Score: 0.106
  4. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72.
    View in: PubMed
    Score: 0.105
  5. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
    View in: PubMed
    Score: 0.073
  6. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3.
    View in: PubMed
    Score: 0.064
  7. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27.
    View in: PubMed
    Score: 0.054
  8. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
    View in: PubMed
    Score: 0.053
  9. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83.
    View in: PubMed
    Score: 0.048
  10. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 01; 64(3):1140-5.
    View in: PubMed
    Score: 0.046
  11. Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37.
    View in: PubMed
    Score: 0.045
  12. Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003 Jul; 74(1):69-80.
    View in: PubMed
    Score: 0.044
  13. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7.
    View in: PubMed
    Score: 0.037
  14. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
    View in: PubMed
    Score: 0.032
  15. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998 Oct 01; 161(7):3347-56.
    View in: PubMed
    Score: 0.032
  16. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10.
    View in: PubMed
    Score: 0.031
  17. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69.
    View in: PubMed
    Score: 0.029
  18. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
    View in: PubMed
    Score: 0.012
  19. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7.
    View in: PubMed
    Score: 0.010
  20. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
    View in: PubMed
    Score: 0.009
  21. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42.
    View in: PubMed
    Score: 0.009
  22. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999 May 05; 81(3):428-37.
    View in: PubMed
    Score: 0.008
  23. Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol. 1993 Jul 01; 151(1):38-47.
    View in: PubMed
    Score: 0.005
  24. Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol. 1992 Aug 15; 149(4):1124-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.